Trial Profile
Phase II Study of Epacadostat (INCB024360) in Combination With Pembrolizumab in Patients With Locally Advanced/Metastatic Sarcoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Haemangioendothelioma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Sarcoma
- Focus Therapeutic Use
- 27 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.
- 27 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.
- 27 Mar 2023 Results published in the Clinical Cancer Research